LivaNova wins FDA approval for aura6000 sleep apnea device

CURRENT BRIEF VERSION: LivaNova has won US FDA premarket approval for its aura6000 System, an implantable hypoglossal nerve stimulation device for adults with moderate to severe obstructive sleep apnea who have failed, can’t tolerate, or aren’t eligible for first-line therapy such as positive airway pressure. The FDA decision was made on March 18, 2026, and publicly announced March 19. According to LivaNova and the FDA’s PMA database, the approval is backed by the OSPREY randomized controlled trial, and the company says the device is the first and only US-approved hypoglossal nerve stimulation therapy without a complete concentric collapse contraindication or warning, and without a pre-implant drug-induced sleep endoscopy requirement. (markets.financialcontent.com)

Why it matters: For veterinary professionals, this is a human medtech story rather than a companion animal care development, but it’s still relevant as a signal of where implantable neuromodulation is heading. The approval broadens the competitive and clinical landscape in sleep apnea, a space previously defined in the US by Inspire’s upper airway stimulation system, and it highlights the FDA’s willingness to clear differentiated neurostimulation approaches when supported by randomized data. In OSPREY, LivaNova previously reported that the trial met primary safety and efficacy endpoints at six months, and later said the 12-month responder rate in the treatment arm was 65%, with response defined as at least a 50% improvement in apnea-hypopnea index and an AHI below 20. More broadly, it fits into a wider FDA pattern of supporting implantable neuromodulation platforms through different regulatory pathways: for example, Nia Therapeutics recently received Breakthrough Device Designation for a fully implantable, closed-loop neurostimulation system for episodic memory loss after traumatic brain injury, based in part on sham-controlled data showing a 19% recall improvement, with an IDE filing planned in 2026. (investor.livanova.com)

What to watch: LivaNova says it expects to launch a next-generation, MRI-compatible version in the first half of 2027, pending FDA review of a PMA supplement. (markets.financialcontent.com)